XML 31 R15.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Non-marketable Securities | 12 Months Ended
--- | ---
Dec. 31, 2023
Non-marketable Securities |
Non-marketable Securities | Note 5 Non-marketable Securities ​ The carrying balance of non-marketable securities are summarized as follows as of the dates indicated: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023 | ​ | December 31, 2022
Federal Reserve Bank stock | ​ | $ | 24,062 | ​ | $ | 18,096
Federal Home Loan Bank stock | ​ | ​ | 16,828 | ​ | ​ | 20,294
Convertible preferred stock | ​ | ​ | 25,000 | ​ | ​ | 29,000
Equity method investments | ​ | ​ | 24,587 | ​ | ​ | 21,659
Total | ​ | $ | 90,477 | ​ | $ | 89,049
​ Non-marketable securities included FRB stock, FHLB stock and other non-marketable securities. During the years ended December 31, 2023 and 2022, purchases of non-marketable securities consisted primarily of FHLB stock, totaled $106.2 million and proceeds of non-marketable securities consisted of redemptions of FHLB stock, totaled $100.0 million. The changes in the Company’s FHLB stock holdings are directly correlated to FHLB line of credit advances and paydowns. During the year ended December 31, 2022, purchases of non-marketable securities totaled $37.3 million, and proceeds from non-marketable securities totaled $4.2 million. ​ FRB and FHLB stock ​ At December 31, 2023 and December 31, 2022, the Company held FRB stock and FHLB stock for regulatory or debt facility purposes. These are restricted securities which, lacking a market, are carried at cost. There have been no identified events or changes in circumstances that may have an adverse effect on the FRB and FHLB stock carried at cost. ​ Other non-marketable securities ​ Other non-marketable securities consist of equity method investments and convertible preferred stock without a readily determinable fair value. During the years ended December 31, 2023 and 2022, the Company recorded net unrealized losses on equity method investments totaling $35 thousand and net unrealized gains on equity method investments totaling $1.4 million, respectively. During the year ended December 31, 2023, the Company recorded $4.0 million in impairments on convertible preferred stock related to venture capital investments. No impairments were recorded during 2022. These gains and losses were recorded in other non-interest income in the Company’s consolidated statements of operations.

X
- Definition Disclosure - Non-Marketable Securities (Narrative) [Abstract] + References No definition available. + Details
Name: | nbhc_DisclosureNonMarketableSecuritiesNarrativeAbstract
Namespace Prefix: | nbhc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities And Nonmarketable Equity Investments [Text Block] + References No definition available. + Details
Name: | nbhc_SecuritiesAndNonmarketableEquityInvestmentsTextBlock
Namespace Prefix: | nbhc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration